Hydrocortisone in depression: Too high, too low or untimely?;Cortisol bij depressie: Te hoog, te laag, of niet op tijd?

Tijdschrift voor Psychiatrie

Volumn 44, Issue 5, 2002, Pages 323-332

  Korf, J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cortisone; Depression; Dexamethasone; Hypothalamus pituitary adrenalaxis (HPA axis)

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ELECTROCONVULSIVE THERAPY; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; RECEPTOR DOWN REGULATION;

EID: 0036073055     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. The dexamethasone suppression test: An overview of its current status in psychiatry
2. Dexamethasone for the treatment of depression: A randomized placebo-controlled, double blind trial
3. Depression in later life: Three etiologically different subgroups
4. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility
5. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind placebo-controlled study
6. Depressive illness
7. De rol van cortisol bij stressgerelateerde geheugenstoornissen
8. Nongenomic transmission across generations of maternal behavior and stress responses in the rat
9. Pituitaryadrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects
10. Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy
11. Klinische consequenties van centrale activatie van de hypothalamus-hypofyse-bijnieras
12. Major depressive disorder: Longitudinal symptomatic structure, relapse and recovery
13. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain
14. Effects of early adverse experiences on brain structure and function: Clinical implications
15. Brain corticosteroid receptor balance in health and disease
16. Considering depression as a consequence of activation of the inflammatory system
17. A functional loop linking cerebral, hormonal and somatic aspects of depression: Vulnerability during neurodevelopment
18. Down-regulation of the hypothalamo-pituitary-adrenal axis reduces brain damage and number of seizures following hypoxia/ischaemia in rats
19. Metyrapone reduces rat brain damage and seizures after hypoxia-ischemia: An effect independent of modulation of plasma corticosterone levels?
20. High and low neuroticism predict different cortisol responses to the combined dexamethasone-CRH test
21. Effects of adverse experiences for brain structure and function
22. Future therapeutic targets in mood disorders: The glucocorticoid receptor
23. Is depression an adaptation?
24. Treatment of major depression with metyrapone and hydrocortisone
25. Pituitary-adrenal axis measures as predictors of sustained remission in major depression
26. Heterogeneous neurochemical responses to different stressors: A test of Selye's doctrine of nonspecificity
27. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment
28. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression
29. The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles
30. Treatment of depression with antiglucocorticoid drugs
31. The DST as a predictor of outcome in depression: A meta-analysis
32. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment
33. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders
34. HPA-axis activity in the etiology and treatment of psychotic depression
35. Clozapine-induced Fos-protein expression in rat forebrain regions: Differential effects of adrenalectomy and corticosterone supplement
36. Care utilization and outcome of DSM-III-R major depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS)
37. Acute cortisol and depression similarly affect emotional memory
38. Antiglucocorticoid treatment of depression: Double blind ketoconazole
39. Ketoconazole administration in hypercortisolemic depression
40. Dexamethason for depression [brief]
41. Dehydroepiandrosterone (DHEA) treatment of depression
42. Endotoxin produces a depression like syndrome in rats
43. Behavioral and psychological effects of immune activation: Implications for 'depression and chronic medical illness'
44. Cortisol response in the combined dexamethasone/CR H test as predictor of relapse in patients with remitted depression: A prospective study